[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-addiction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-addiction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100342953","outcome-inference-in-the-sensory-preconditioning-task-in-opioid-use-disorder-100342953",false,"NCT03745339","Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder","Outcome Inference in the Sensory Preconditioning Task in Opioid-use Disorder","* INCLUSION CRITERIA:\n\nThe enrollment target for the protocol is 120 (40 healthy controls, 40 patients on agonist maintenance, and 40 participants who have met DSM 5 criteria for OUD, but are now abstinent (for at least 3 weeks) and not on agonist maintenance.\n\nAll Participants\n\n* Age between 21 and 65 years inclusive. Rationale: objective olfactory impairment grows more prevalent with age; after age 53, the prevalence is 24.5%, increasing to 62.5 % in people aged 80-97 years.\n* Willing to fast for at least 6 hours prior to the study session and be exposed to food odors. These will be assessed with the \"019 Additional History Form\" questionnaire.\n\nAdditional Criteria for Abstinent OUD group\n\n* History of opioid-use disorder (DSM-5), to be assessed via the Mini International Neuropsychiatric Interview (MINI) or the Structured Clinical Interview for DSM-5 (SCID). History of SUDs can include substances in addition to opioids (e.g., cocaine).\n* Abstinent \\> 3 weeks from all illicit substances (tobacco smoking and nondependent drinking permissible), to be assessed via 30-day timeline follow-back calendar. (Current abstinence will be confirmed via urine screen: see exclusion criteria.) Rationale: Although heterogeneity will be considerable, what all enrollees will have in common is having become abstinent from opioids long enough to be past withdrawal symptoms. Their heterogeneity in duration of abstinence and other drug-history measures will enable us to examine relationships between those things and inferencing performance.\n\nAdditional Criteria for In-treatment OUD group\n\n-Current enrollment in treatment for OUD with buprenorphine or methadone (\\>3 weeks on stable dose). Current use of illicit substances during treatment is permissible but not required. Rationale: Again, heterogeneity will be considerable, but what all enrollees will have in common is having sought treatment for their OUD and being currently maintained on an agonist that permits adaptive everyday functioning. Their heterogeneity in ongoing use of illicit substances will enable us to examine relationships between inferencing performance and treatment response.\n\nEXCLUSION CRITERIA:\n\nAll participants\n\n* Anosmia, dysosmia, or hyposmia (poor olfactory function), to be assessed via Sniffin Sticks threshold test \\\u003C4 or via Sniffin Sticks odor identification test \\\u003C10.\n* History of any neurological condition resulting in inability to perform study task. Examples include but not limited to degenerative processes of the CNS (Parkinson disease, Alzheimer disease); other neurologic diseases (Huntington disease, multiple sclerosis, other motor-neuron diseases); inflammatory conditions (sarcoidosis, Wegener granulomatosis); or significant cerebrovascular disease including (but not limited to) epilepsy, stroke, or meningitis; traumatic brain injury (TBI) or major head trauma with sustained loss of consciousness (\\>30 min). To be assessed by history and physical and evaluation to sign screening consent. Eligibility will be determined based on MAI review of participants ability to perform study task. MAI will consider but is not limited to H and P results for mental status exam, language exam, and attention span exam. Rationale: any of these could impair task performance.\n* History of current (past 12 months) uncontrolled DSM-5 major psychiatric disorder including major affective disorder, obsessive-compulsive disorder, schizophrenia, and PTSD. (Candidates will not be excluded for a history of major psychiatric disorder that is now being successfully treated.) To be assessed by MINI or SCID interview. Rationale: could impair task performance.\n* History of anaphylaxis due to, e.g., significant asthma, food or non-food allergy, or intolerance to odors (including latex, detergents, soaps, etc.). To be assessed by history and physical. Rationale: could make odorant exposure risky.\n* Current use of medications or substances that affect alertness and that cannot be withheld on the morning of the study visit (e.g., barbiturates, benzodiazepines, cannabinoids, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, etc.). To be assessed by history and physical. Whether candidate will be requested to withhold any medication will be determined based on MAI judgment. Additionally, if participant has a BrAC \\>0.08, MAI will use clinical judgement to determine if participant should be rescheduled. Rationale: could impair task performance.\n* For women: pregnancy. To be assessed by history and physical and by urine testing. Rationale: Could affect task performance-physiological and hormonal changes during pregnancy influence rhinological function.\n* Any other medical illness or condition that in the judgment of the investigators is incompatible with study participation.\n\nAdditional criteria for Control Group\n\n* History of a substance-use disorder (except nicotine, for matching purposes), or current use of any drug for nonmedical purposes. Controls, who cannot have a history of OUD, will be assessed by their medical history and physical examination for the presence of any signs or symptoms consistent with opioid withdrawal. Any Control with any sign or symptom consistent with opioid withdrawal will be evaluated by the MAI to rule out opioid withdrawal if possible.\n* Urine positive for any illicit drug. Rationale: Controls should have no drug use. A UDS that is positive for a prescribed medication that the MAI has determined is not due to illicit drug use will not be exclusionary.\n\nAdditional criteria for Abstinent Group\n\n* Urine positive for any illicit drug. Rationale: Abstinent OUD group should have no drug use in the last 3 weeks which would include the several-day time frame to which urine screens are sensitive. A UDS that is positive for a prescribed medication that the MAI has determined is not due to illicit drug use will not be exclusionary.\n* Current signs or symptoms of opioid withdrawal. These will be assessed in the Abstinent group via the Clinical Opioid Withdrawal Scale (COWS) and the Subjective Opioid Withdrawal Scale (SOWS).\n\nAdditional criteria for In-treatment OUD group\n\n-Urine negative for opioid agonist that the participant is taking as part of their OUD treatment. Rationale: In-treatment OUD group should be in treatment. A negative test suggests the participant is not adhering to their treatment plan. In-treatment OUD participants may test positive for other substances as well as their opioid agonist because they may have ongoing illicit drug use.",true,"ALL","21 Years","60 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","Background:\n\nPeople with addictions often find it hard to choose the long-term benefits of abstinence over the short-term effects of using drugs. Researchers think this is partly due to parts of the brain involved in certain types of learning and decision-making. Researchers want to test these basic functions using a simple task with pictures and odors.\n\nObjective:\n\nTo see if performance in a learning task differs between people who have opioid-use disorder and people who don t.\n\nEligibility:\n\nAdults 21-60 years old who are willing to fast for at least 6 hours and smell food odors. Those with an opioid-use disorder must either not use for at least 3 weeks or be in treatment.\n\nDesign:\n\nParticipants will have 1 visit that will take up to 5 hours.\n\nBefore the visit, participants will be asked to not eat or drink anything except water for at least 6 hours.\n\nAt the visit, participants will be checked for signs of intoxication.\n\nParticipants will give urine and breath samples.\n\nParticipants will have tests of learning and behavior. They will look at shapes on a computer screen. The shapes will be paired with different food odors.\n\nThe odors will come from a sterile tube placed under the nose.\n\nParticipants will have their breathing monitored with a belt around the upper abdomen.\n\nAbout 30 days and 60 days later, participants will be called and asked about their drug use over the past 30 days.",[26,27],"Opioid-Related Disorders","Drug Addiction",[29,30,31,32,33],"Addiction","Orbitofrontal Cortex","Associative Learning","Implicit Learning","Natural History","RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2019-06-07",{"date":42,"type":22},"2026-10-01",{"name":44,"class":45},"National Institute on Drug Abuse (NIDA)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100595536","the-health-of-women-monitored-in-the-addiction-department-of-the-strasbourg-university-hospitals-100595536","NCT07033728","The Health of Women Monitored in the Addiction Department of the Strasbourg University Hospitals","Santé-Fem","Inclusion Criteria:\n\n* Female, adult (≥ 18 years old)\n* Undergoing follow-up at the CSAPA Addictions Department of the HUS\n* Having met the team's midwife at least once\n* Absence of written objection in the patient's medical record regarding the reuse of her data for scientific research purposes.\n\nExclusion Criteria:\n\n* Absence of written objection in the patient's medical record regarding the reuse of her data for scientific research purposes\n* Female minor\n* Female who has not initiated follow-up with the CSAPA team\n* Women who have never had a consultation with the team's midwife","FEMALE","18 Years",{"count":57,"type":22},55,"The health of women suffering from addiction is little known and little explored in the literature. Indeed, they represent only 20% of addicted patients in general and are encountered primarily during pregnancy or complex situations involving young children.\n\nIn the Addiction Department of Strasbourg University Hospitals, the investigators have established a midwifery consultation exclusively for women of all ages.\n\nDuring the treatment of the women, the investigators were able to identify the specific issues faced by women suffering from addiction and the specific care requirements for this population.",[27],[27,29],"2025-06-13",{"date":63,"type":38},"2025-06-24",{"date":65,"type":38},"2025-03-24",{"date":67,"type":22},"2026-09-24",{"name":69,"class":70},"University Hospital, Strasbourg, France","OTHER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":46},"100480348","long-term-treatment-of-opioid-use-disorder-100480348","NCT05534815","Long-Term Treatment of Opioid Use Disorder","Inclusion Criteria:\n\n* ≥18 years old\n* are enrolled at REACH for buprenorphine or methadone maintenance treatment\n* unemployed\n\nExclusion Criteria:\n\n* Applicants will be excluded if they report recent hallucinations and if they are currently a prisoner.",{"count":78,"type":22},225,"INTERVENTIONAL",[81],"NA","Poverty and opioid addiction are interrelated and chronic problems which have not been addressed adequately. The Therapeutic Workplace could treat the many adults with opioid use disorder who are unemployed and live in poverty. The Therapeutic Workplace pays participants to work. To promote drug abstinence, the Therapeutic Workplace arranges employment-based abstinence reinforcement in which participants are required to provide drug-free urine samples to maintain maximum wages. Many studies have shown that employment-based abstinence reinforcement in the Therapeutic Workplace can promote and maintain drug abstinence. Recently, the investigators showed that abstinence-contingent wage supplements in the Therapeutic Workplace could promote drug abstinence and employment and reduce poverty. However, the investigators have not demonstrated the real-world impacts of the Therapeutic Workplace. The Therapeutic Workplace requires two modifications to produce real world impacts.\n\n1. The investigators must develop a real-world version of the Therapeutic Workplace that community treatment programs can implement.\n2. The investigators must reduce the costs of maintaining employment-based abstinence reinforcement.\n\nThis application seeks to develop and evaluate a low-cost Therapeutic Workplace that community treatment programs can implement and that addresses the persistent nature of opioid addiction and poverty. The investigators propose to conduct a Stage III study in which a community clinic (REACH Health Services) adapts and implements the Therapeutic Workplace intervention. To improve the feasibility of this intervention, the investigators will use low-cost abstinence-contingent wage supplements to maintain abstinence. The investigators propose to conduct a randomized controlled study to evaluate the effectiveness of the low-cost abstinence-contingent wage supplements in a community Therapeutic Workplace to maintain long-term drug abstinence and employment, and to reduce poverty in adults with opioid use disorder. All participants will be invited to attend a 4-week induction period and 48 weeks of support by an employment specialist. At the end of a 4-week induction period, REACH unemployed methadone or buprenorphine patients with opioid use disorder who meet the Induction Period inclusion criteria (N=225) will be randomly assigned to a \"Usual Care Control,\" an \"Initiation Only,\" or an \"Initiation and Maintenance\" group. All groups will be offered methadone or buprenorphine treatment and an employment specialist for 48 weeks. \"Initiation Only\" and \"Initiation and Maintenance\" participants will earn high magnitude abstinence-contingent wage supplements during a 24-week Initiation period (weeks 1-24). \"Initiation and Maintenance\" participants will also earn low-magnitude abstinence-contingent wage supplements during a 24-week Maintenance period (weeks 25-48). The investigators will base the primary outcome measures on assessments conducted every four weeks of the Maintenance period. If low-cost abstinence-contingent wage supplements in the community Therapeutic Workplace maintain drug abstinence and employment and decrease poverty, community drug abuse treatment clinics could apply this intervention widely as a long-term maintenance treatment for unemployed adults with opioid use disorder.",[27,84],"Employment","2025-04-29",{"date":87,"type":38},"2025-05-02",{"date":89,"type":38},"2023-03-01",{"date":91,"type":22},"2028-02-29",{"name":93,"class":70},"Northern Michigan University"]